Eli Lilly picks up another Covid-19 EUA as regulators wave through its Olumiant plus remdesivir combo
Eli Lilly has picked up another win at the FDA, crossing the finish line again in the Covid-19 treatment race despite some mixed data. And the authorization comes before Regeneron’s antibody therapy, which notably was used to treat President Donald Trump back in October, could pick up an EUA.
Regulators have given the green light to Lilly’s Olumiant, in combination with Gilead’s remdesivir, to treat suspected or confirmed Covid-19 cases in both hospitalized adults and children over 2 that need supplemental oxygen, ventilators or life support. The authorization was based on data showing the median time to recovery from Covid-19 was seven days on the combo vs. eight days for remdesivir by itself.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.